Carbohydrate: Current role in diabetes mellitus and metabolic disease;Hidratos de carbono: Actualización de su papel en la diabetes mellitus y la enfermedad metabólica

Nutricion Hospitalaria

Volumn 30, Issue 5, 2014, Pages 1020-1031

  Lopez, Victoria Luna ^a   Antonio Lopez Medina, Jose ^b   Gutierrez, Mercedes Vazquez ^c   Luisa Fernandez Soto, M ^d  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL TORRECÁRDENAS   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Carbohydrates; Diabetes mellitus; Enteral nutrition; Metabolic disease; Obesity

Indexed keywords

CARBOHYDRATE DIET;

ADVERSE EFFECTS; CALORIC INTAKE; CARBOHYDRATE DIET; DIABETES MELLITUS; HUMAN; METABOLIC DISEASES; NUTRITIONAL REQUIREMENT; OBESITY;

DIABETES MELLITUS; DIETARY CARBOHYDRATES; ENERGY INTAKE; HUMANS; METABOLIC DISEASES; NUTRITIONAL REQUIREMENTS; OBESITY;

EID: 84908702386     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.30.5.7475     Document Type: Article

References (73)

1. Gomez Candela C, Palma Milla S. Una vision global, actualizada y critica, del papel del azucar en nuestra alimentacion. Nutr Hosp 2013; 28 (4):1-4.
2. Food and Agricultural Organization/World Health Organization (FAO/WHO). Carbohydrates in human nutrition. Report of a Joint FAO/WHO Expert Consultation. FAO Food Nutr Pap 1998; 66:1-140.
3. Mann J, Cummings JH, Englyst HN, Key T, Liu S, Riccardi G, et al. FAO/WHO Scientific Update on carbohydrates in human nutrition: conclusions. Eur J Clin Nutr 2007; 61: S132-7.
4. Plaza-Diaz J, Martinez Agustin O, Gil Hernandez G. Los alimentos como fuente de mono y disacaridos: aspectos bioquimicos y metabolicos. Nutr Hosp 2013; 28 (4):5-16.
5. Bengmark R, Gil A, Productos finales de la glicacion y de la lipoxidacion como amplificadores de la inflamacion: papel de los alimentos. Nutr Hosp 2007; 22 (6):625-40.
6. Slavin J. Fiber and Prebiotics: Mechanisms and Health Benefits. Nutrients 2013; 5: 1417-35.
7. Soriguer F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia 2012; 55:89-93.
8. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25:608-13.
9. Wolever TM, Mehling C. Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concen-trations in subjects with impaired glucose tolerance. Am J Clin Nutr 2003; 77: 612-21.
10. Franz MJ, Powers MA, Leontos C, Holzmeister LA, Kulkami K, Monk A et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc 2010; 110:1852-89.
11. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:285-93.
12. Ajala O, English P, Pinkney J. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. Am J Clin Nutr 2013; 97: 505-16.
13. Mann J., Te Morenga L. Diet and diabetes revisited, yet again. Am J Clin Nutr 2013; 97: 453-4.
14. Foster GD, Wyatt HR, Hill JO, Makris AP, Rosenbaum DL, Brill C et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low fat diet: a randomized trial. Ann Intern Med 2010; 153:147-57.
15. Shai I, Schwarzfuchs D, Henkin Y, Danit RS, Witkow S, Greenberg I et al. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359: 229-41.
16. Esposito K, Maiorino MI, Ciotola M, Di Palo C, Scognamiglio P, Gichino M et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med 2009; 151:306-14.
17. Foo SY, Heller ER, Wykrzykowska J, Sullivan CJ, Manning-Tobin JJ, Moore Kj et al. Vascular effects of a low-carbohydrate high-protein diet. Proc Natl Acad Sci 2009; 106: 418-23.
18. American Diabetes Association (ADA). Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care 2014; 37 (Suppl.1):121-43.
19. Canadian Diabetes Association (CDA). Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Canadian Journal of Diabetes 2013; 37(Suppl. 1): 45-55.
20. Barnard ND, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Jaster B et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care 2006; 29: 1777-83.
21. Diabetes and Nutrition Study Group of the European Association for The Study of Diabetes. Recommendations for the nutritional management of patients with diabetes mellitus. Eur J Clin Nutr 2000; 54: 353-5.
22. Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev 2009; CD006296.
23. Hauner H, Bechthold A, Boeing H, Bronstrup A, Buyken A, Leschik-Bonnet E et al. Evidence-based guideline of the German Nutrition Society: carbohydrate intake and prevention of nutrition-related diseases. Ann Nutr Metab 2012; 60 (Suppl. 1):1-58.
24. Wolever TM, Gibbs AL, Mehling C, Chiasson JL, Connelly PW, Josse RJ et al. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reative protein. Am J Clin Nutr 2008; 87:114-25.
25. Sluijs I, Beulens JW, Van der Schouw YT, Van der A DL, Buckland G, Kuijsten A et al. Dietary glycemic index, glycemic load, and digestible carbohydrate intake are not associated with risk of type 2 diabetes in eight European countries. J Nutr 2013; 143: 93-9.
26. Livesey G, Taylor R, Livesey H, Liu S. Is there a dose-response relation of dietary glycemic load to risk of type 2 diabetes? Meta-analysis of prospective cohort studies. Am J Clin Nutr 2013; 97:584-96.
27. Sievenpiper JL, Chiavaroli L, de Souza RJ, Mirrahimi A, Cozma AI, Ha V et al. “Catalytic” doses of fructose may benefit glycaemic control without harming cardiometabolic risk factors: a small meta-analysis of randomised controlled feeding trials. Br J Nutr 2012; 108:418-23.
28. Sievenpiper JL, Carleton AJ, Chatha S, Jiang HY, de Souza RJ, Beyene J et al. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care 2009; 32: 1930-7.
29. Montonen J, Jarvinen R, Knekt P, Heliovaara M, Reunanen A. Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. J Nutr 2007; 137: 1447-54.
30. Cook Cb, Kongable GL, Potter DJ, Abad VJ, Lejia DF, Anderson M. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. J Hosp Med 2009; 4:E7-14.
31. Pasquel FJ, Spiegelman R, McCauley M, et al..Hyperglycemia during total parenteral nutrition: an important marker of por outcome and mortality in hospitalized patients. Diabetes Care 2010; 33(4):739-741.
32. Gabriel Olveira, Maria Jose Tapia, Julia Ocon, Carmen Cabrejas Gomez, Maria Doloes Ballesteros Pomar, Alfonso Vidal Casariego, et al. Parenteral Nutrition-Associated Hyperglycemia in Non-Critically ill Inpatients Increases the Risk of In-Hospital Mortality (Multicenter Study). Diabetes Care 2013; 36:1061-66.
33. Marik PE, Raghavan M. Stress hyperglycemia insulin and immunomodulation in sepsis. Intensive Care Med 2004; 30:748-56.
34. Umpierrez G, Isaacs S, Bazargan N, You X, Thaler L, Kibabchi A. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002; 87:978-82.
35. Garcia de Lorenzo A, Rodriguez Montes JA. Hiperglucemia en el paciente critico. Nutr Hosp 2010; 3:46-50.
36. Gustafsson UO, Scott MJ, Schwenk W, N. Demartines, D. Roulin N. Francis E. et al. Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS) Society recommendations. Clin Nutr 2012; 31:783-800.
37. Wang ZG, Wang Q, Wang WJ, Qin HL. Randomized clinical trial to compare the effects of preoperative oral carbohydrate versus placebo on insulin resistance after colorectal surgery. Br J Surg 2010; 97: 317-27.
38. Garcia de Lorenzo Mateos A, Rodriguez-Montes JA. Hiperglucemia en el paciente critico. Nutr Hosp 2010; 3(1):46-50
39. Gianotti L, Braga M. Revising concepts of artificial nutrition in contemporary surgery: from energy and nitrogen to immuno-metabolic support. Nutr Hosp 2011; 26(1):56-67.
40. Gonzalez-Infantino CA, Gonzalez CD, Sanchez R, Presner N. Hyperglycemia and hypoalbuminemia as prognostic factors in patients with enteral feeding. Nutrition 2013; 29:497-501.
41. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. ACE/ADA Task Force on Inpatients Diabetes. Endocr Pract 2006; 12: (3):4-13.
42. De Luis DA, Izaola O, de la Fuente B, Terroba MC, Cuellar L, Cabezas G. A randomized clinical trial with two doses of an enteral diabetes-specific suplements in elderly patients with diabetes mellitus type 2. Eur Rev Med and Pharmacol Sci 2013;17 (12):1626-30.
43. Stanhope KL, Havel PJ. Fructose consumption: considerations for future research on its effects on adipose distribution, lipids metabolisms, and insulin sensitivity in humans. J Nutr 2009;139:1236-41.
44. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N) Board of Directors. Clinical guidelines: Nutrition support of adult patients with hyperglycemia. J Parenter Enteral Nutr 2013; 37:23-36.
45. Garcia-Gutierrez CE, Mesa MD, Olza J, Buccianti G, Perez M, Moreno-Torres R et al. Postprandial glucose, insulin, and gastrointestinal hormones in healthy and diabetic subjects fed a fructose-free and resistant starch type-IV enriched enteral formula. Eur J Nutr 2012:7:67-71.
46. Voss AC, Maki KC, Garvey WT, Hustead DS, Alish C, Fix B, et al. Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. Nutrition 2008; 24(10): 990-97.
47. Leon-Sanz M, Garcia-Luna PP, Sanz Paris A, et al. Glycemic and lipid control in hospitalized type 2 diabetic patients: evaluation of 2 enteral nutrition formulas (low carbohydrate-high monounsaturated fat vs high carbohydrate). JPEN 2005; 29(1):21-29.
48. Mesejo A, Acosta JA, Ortega C. Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patient. Clin Nutr 2003; 32(3): 295-305.
49. De Luis D, Izaola O, de la Fuente B, Araujo K. Blood glucose and insulin responses to two hypocaloric enteral formulas in patients with diabetes mellitus type 2. Nutr Hosp 2013: 28(3):600-96.
50. Mc Mahon MM, Nystrom E, Braunschweig C, Miles J, Compher CH and the A.S.P.E.N Board of Directors. ASPEN Clinical guidelines: Nutrition support of adult patients with hyperglycemia. JPEN 2013; 37(23):23-36.
51. Alish CJ, Garvey WT, Maki KC, Sacks GS, Hustead DS, Hegazi RA, et al. A diabetes-specific enteral formula improves glycemic variability in patient s with type 2 diabetes. Diabetes Technol Ther 2010; 12:419-25.
52. ELia M, Ceriello A, Heiner L et al. Enteral nutritional support and use of diabetes-eespecific formulas for patients with diabetes: A systematic review and meta-analysis. Diabetes Care 2005; 28(9):2267-89.
53. Santiago P, Garcia E, Sanchez C, Moreno A, Martinez P, Sanchez B, et al. Estudio antropometrico de los escolares de la provincia de Jaen. Endocrinol Nutr 2007; 54(4):205-10.
54. Katherine M, Brian K, Heather O, Barry I. Association of all cause mortality with overweight and obesity using standard body mass index categories: A systematic review and metaanalysis. JAMA 2013; 309 (1): 71-82.
55. Morris JN. Obesity in Britain: lifestyle data do not support sloth hypothesis. BMJ 1995; 311: 1568-9.
56. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr 2007; 86: 899-906.
57. http://www.ncbi.nlm.nih.gov/pubmed/?term=sugar+and+obesity; ;http://www.ncbi.nlm.nih.gov/pubmed/?term=sugar+and+ cardiovascular+disease
58. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight: systematic review and meta-analyses of randomised controlled trials and cohort studies. BMJ 2012; 15; 346-53.
59. James J, Thomas P, Cavan D, Kerr D. Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. BMJ 2004; 328:1237-43.
60. Swanson JE, Laine DC, Thomas W, Bantle JP. Metabolic effects of dietary fructose in healthy subjects. Am J Clin Nutr 1992; 55:851-6.
61. Ebbeling CB, Feldman HA, Chomitz VR, Antonelli TA, Gortmaker SL, Osganian SK et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med 2012; 367:1407-16.
62. De Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367:1397-406.
63. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, Jackson AU et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42:937-48.
64. Qibin Q, Audrey Y, Kang J, Jense MK, Curhan GC, Pasquale LR. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med 2012; 367: 1387-96.
65. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake Neurosci Biobehav Rev. 2008; 32(1): 20-39.
66. Agius L. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochem Pharmacol 2013;85(3):306-12.
67. Zoppini G, Targher G, Bonora E. The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review. J Endocrinol Invest 2011; 34 (11):881-6.
68. Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDLcholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 2011; 96:1596-605.
69. Riveros MJ, Parada A, Petinelli P. Consumo de fructosa y sus implicaciones para la salud; malabsorcion de fructosa e higado graso no alcoholico. Nutr Hosp 2014;29(3):491-9.
70. Delzenne NM, Neyrinck AM, Backhed F, Cani PD. Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 2011; 7: 639-46.
71. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 1518-23.
72. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444:1027-31.
73. Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Practice & Research Clinical Gastroenterology 2013; 27: 73-83.